1. Home
  2. VERU vs SNCR Comparison

VERU vs SNCR Comparison

Compare VERU & SNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VERU
  • SNCR
  • Stock Information
  • Founded
  • VERU 1971
  • SNCR 2000
  • Country
  • VERU United States
  • SNCR United States
  • Employees
  • VERU N/A
  • SNCR N/A
  • Industry
  • VERU Biotechnology: Pharmaceutical Preparations
  • SNCR EDP Services
  • Sector
  • VERU Health Care
  • SNCR Technology
  • Exchange
  • VERU Nasdaq
  • SNCR Nasdaq
  • Market Cap
  • VERU 54.6M
  • SNCR 61.5M
  • IPO Year
  • VERU 1990
  • SNCR 2006
  • Fundamental
  • Price
  • VERU $3.75
  • SNCR $4.96
  • Analyst Decision
  • VERU Strong Buy
  • SNCR Strong Buy
  • Analyst Count
  • VERU 3
  • SNCR 1
  • Target Price
  • VERU $33.33
  • SNCR $13.00
  • AVG Volume (30 Days)
  • VERU 139.0K
  • SNCR 66.2K
  • Earning Date
  • VERU 12-15-2025
  • SNCR 11-04-2025
  • Dividend Yield
  • VERU N/A
  • SNCR N/A
  • EPS Growth
  • VERU N/A
  • SNCR N/A
  • EPS
  • VERU N/A
  • SNCR N/A
  • Revenue
  • VERU $16,886,419.00
  • SNCR $171,870,000.00
  • Revenue This Year
  • VERU N/A
  • SNCR $1.36
  • Revenue Next Year
  • VERU N/A
  • SNCR $5.22
  • P/E Ratio
  • VERU N/A
  • SNCR N/A
  • Revenue Growth
  • VERU 337.24
  • SNCR 2.54
  • 52 Week Low
  • VERU $2.64
  • SNCR $4.83
  • 52 Week High
  • VERU $14.20
  • SNCR $12.85
  • Technical
  • Relative Strength Index (RSI)
  • VERU 47.71
  • SNCR 35.75
  • Support Level
  • VERU $3.61
  • SNCR $4.83
  • Resistance Level
  • VERU $3.99
  • SNCR $5.50
  • Average True Range (ATR)
  • VERU 0.30
  • SNCR 0.26
  • MACD
  • VERU -0.10
  • SNCR -0.01
  • Stochastic Oscillator
  • VERU 14.52
  • SNCR 13.40

About VERU Veru Inc.

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

About SNCR Synchronoss Technologies Inc.

Synchronoss Technologies Inc is a provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.

Share on Social Networks: